The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Iunilaĭnen O.A.

FGBU "ndokrinologicheskiĭ nauchnyĭ tsentr" Minzdrava Rossii

Starostina E.G.

FGUZ "Moskovskiĭ nauchno-issledovatel'skiĭ klinicheskiĭ institut (MONIKI) im. M.F. Vladimirskogo"

Dzeranova L.K.

ndokrinologicheskiĭ nauchnyĭ tsentr Minzdrava RF, Moskva

Kudryashkina G.N.

Psychiatric City Hospital №1, Moscow, Russia

Kesselman L.G.

Psychiatric City Hospital №1, Moscow, Russia

Baranov P.A.

Russian Medical Academy of Postgraduate Education, Moscow, Russia

Dedov I.I.

Endocrinology Research Centre

Hyperprolactinemia associated with neuroleptic treatment: clinical characteristics and an impact on sexual function

Authors:

Iunilaĭnen O.A., Starostina E.G., Dzeranova L.K., Kudryashkina G.N., Kesselman L.G., Baranov P.A., Dedov I.I.

More about the authors

Read: 2946 times


To cite this article:

Iunilaĭnen OA, Starostina EG, Dzeranova LK, Kudryashkina GN, Kesselman LG, Baranov PA, Dedov II. Hyperprolactinemia associated with neuroleptic treatment: clinical characteristics and an impact on sexual function. S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(11):17‑25. (In Russ.)
https://doi.org/10.17116/jnevro201611611117-25

Recommended articles:
The role of immuno-inflammatory factors in the deve­lopment of nega­tive symptoms in schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):42-48
A role of transcription factors in pathogenic processes asso­ciated with schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):49-54
Meta­bolic syndrome and anti­psychotic therapy of schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):165-170
PANSS six-factor model. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):28-34
Clinical and immu­nological rela­tionships in patients with early schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):35-42
Clinical and psychopathological features of treatment-resistant schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):43-50
Lactational mastitis after mammoplasty. Plastic Surgery and Aesthetic Medi­cine. 2025;(2):128-133

References:

  1. Wieck A, Haddad P. Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences. The British Journal of Psychiatry. 2003;182:199-204. doi: 10.1192/bjp.182.3.199
  2. Canuso C, Goldstein J, Wojcik J et al. Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder. Psychiatry Res. 2002;111(1):11-20. doi: 10.1016/S0165-1781(02)00123-3
  3. Smith S, Wheeler M, Murray R et al. The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis. Journal of Clinical Psychopharmacology. 2002;22(2):109-114. doi:10.1097/00004714-200204000-00002
  4. Johnsen E, Kroken R, Abaza M et al. Antipsychotic-inducedhyperprolactinemia: a cross-sectional survey. J Clin Psychopharmacol. 2008;28(6):686-690. doi: 10.1016/j.schres.2007.12.383
  5. Baptista T, Molina M, Martinez J et al. Effects of the antipsychotic drug sulpiride on reproductive hormones in healthy premenopausal women: relationship with body weight regulation. Pharmacopsychiatry. 1997;30(6):256-262. doi:10.1055/s-2007-979503
  6. Kinon B, Gilmore J, Liu H et al. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology. 2003;28(suppl 2):55-68. doi:10.1016/s0306-4530(02)00127-0
  7. Prentice D, Deakin J. Role of neuroleptic drugs and organic mechanisms in the aetiology of menstrual irregularities in schizophrenic women. Schizophrenia Research. 1992;6:114-118. doi: 10.1016/0920-9964(92)90144-t
  8. Eberhard J, Lindstrom E, Holstad M et al. Prolactin level during 5 years of risperidone treatment in patients with psychotic disorders. Acta Psychiatr Scand. 2007;115(4):268-276. doi: 10.1111/j.1600-0447.2006.00897.x
  9. Neovius M, Eberhard J, Lindström E et al. Weight development in patients treated with risperidone: a 5-year naturalistic study. Acta Psychiatr Scand. 2007;115(4):277-285. doi: 10.1111/j.1600-0447.2006.00899.x
  10. Melkersson K, Berinder K, Hulting A. Effect of antipsychotic-induced hyperprolactinemia on anthropometric measures, insulin sensitivity and lipid profile in patients with schizophrenia or related psychoses. Neuro Endocrinol Lett. 2011;32(4):428-436.
  11. Baptista T, Lacruz A, Meza T et al. Antipsychotic drugs and obesity: is prolactin involved? Can J Psychiatry. 2001;46(9):829-834.
  12. O’Keane V, Meaney A. Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia? J Clin Psychopharmacol. 2005;25(1):26-31. doi: 10.1097/01.jcp.0000150223.31007.e0
  13. Kishimoto T, Watanabe K, Shimada N. Antipsychotic-induced hyperprolactinemia inhibits the hypothalamo-pituitary-gonadal axis and reduces bone mineral density in male patients with schizophrenia. J Clin Psychiatry. 2008;69(3):385-391. doi: 10.4088/jcp.v69n0307
  14. Bergemann N, Mundt C, Parzer P. Plasma concentrations of estradiol in women suffering from schizophrenia treated with conventional versus atypical antipsychotics. Schizophr Res. 2005;73(2-3):357-366. doi: 10.1016/j.schres.2004.06.013
  15. Kinon B, Gilmore J, Liu H et al. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology. 2003;28(suppl 2):55-68. doi: 10.1016/s0306-4530(02)00127-0
  16. Kaneda Y. The impact of prolactin elevation with antipsychoticmedications on subjective quality of life in patients with schizophrenia. Clin Neuropharmacol. 2003;26(4):182-184. doi: 10.1097/00002826-200307000-00006
  17. Serretti A, Chiesa A. A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics. Int Clin Psychopharmacol. 2011;26(3):130-140. doi: 10.1097/yic.0b013e328341e434
  18. Knegtering H, Boscha R, Casteleina S et al. Are sexual side effects of prolactin-raising antipsychotics reducible to serum prolactin? Psychoneuroendocrinology. 2008;33:711—71756. doi: 10.1016/j.psyneuen.2008.02.008
  19. Rettenbacher M, Hofer A, Ebenbichler C et al. Prolactin levels and sexual adverse effects in patients with schizophrenia during antipsychotic treatment. J Clin Psychopharmacol. 2010;30(6):711-715. doi: 10.1097/jcp.0b013e3181faf0e3
  20. Knegtering R, Castelein S, Bous H et al. A Randomized Open-Label Study of the Impact of Quetiapine Versus Risperidone on Sexual Functioning. Journal of Clinical Psychopharmacology. 2004;24(1):56-61. doi: 10.1097/01.jcp.0000106220.36344.04
  21. Johnsen E, Kroken R, Løberg E et al. Sexual Dysfunction and Hyperprolactinemia in Male. Psychotic Inpatients: A Cross-Sectional Study. Advances in Urology. 2011;6-14. doi: 10.1155/2011/686924
  22. Smith SM, O’Keane V, Murray R et al. Sexual dysfunction in patients taking conventional antipsychotic medication. Br J. 2002;63:763-771. doi: 10.1016/s0920-9964(00)90844-2
  23. Mel'nichenko GA, Goncharov NP, Dzeranova LK. i dr. Klinicheskie i laboratornye aspekty issledovanija izoform prolaktina metodom PJeG-precipitacii i ul'trafil'tracii. Problemy Jendokrinologii. 2010;(1):19-25. (In Russ.). doi: 10.14341/probl201056119-25
  24. Nakonezny P, Byerly M, Rush A. The relationship between serum prolactin level and sexual functioning among male outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind trial of risperidone vs. quetiapine. J Sex Marital Ther. 2007;33(3):203-216. doi:10.1080/00926230701267829
  25. Westheide J, Cvetanovska G, Albrecht C et al. Prolactin, subjective well-being and sexual dysfunction: an open label observational study comparing quetiapine with risperidone. J Sex Med. 2008;5(12):2816-2826. doi: 10.1111/j.1743-6109.2008.00859.x
  26. Konarzewska B, Wołczyński S, Szulc A et al. Effect of risperidone and olanzapine on reproductive hormones, psychopathology and sexual functioning in male patients with schizophrenia. Psychoneuroendocrinology. 2009;34(1):129-139. doi: 10.1016/j.psyneuen.2008.08.015
  27. Yasui-Furukori N, Fujii A, Sugawara N et al. No association between hormonal abnormality and sexual dysfunction in Japanese schizophrenia patients treated with antipsychotics. Hum Psychopharmacol. 2012;27(1):82-89. doi: 10.1002/hup.1275
  28. Junilajnen OA, Starostina EG, Dzeranova LK. i dr.Jepidemiologicheskie harakteristiki giperprolaktinemii,associirovannoj s priemom nejroleptikov. Sovremennaja terapija v psihiatrii i nevrologii. 2014;(4):4-9. (In Russ.).
  29. Lingjaerde O, Ahlfors U, Bech P et al. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand. 1987;334:1-100. doi: 10.1111/j.1600-0447.1987.tb10566.x
  30. Montejo AL, Rico-Villademoros F. Psychometric properties of the Psychotropic-Related Sexual Dysfunction Questionnaire (PRSexDQ-SALSEX) in patients with schizophrenia and other psychotic disorders. Journal of Sex & Marital Therapy. 2008;34(3):227-239. doi: 10.1080/00926230701866125
  31. Malik P, Kemmler G, Hummer M et al. Sexual dysfunction in first-episode schizophrenia patients: results from European First Episode Schizophrenia Trial. J Clin Psychopharmacol. 2011;31(3):274-280. doi: 10.1097/jcp.0b013e3182199bcc

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.